Marty L. Slattery

Marty L. Slattery, PhD, MPH

Languages spoken: English

Academic Information

Departments Emeritus - Internal Medicine

Divisions: Epidemiology

Academic Office Information

marty.slattery@hsc.utah.edu

Research Interests

  • Epidemiologic Methods
  • Environmental Factors
  • Cancer Genetics
  • Cancer Epidemiology
  • Dietary Patterns
  • Physical Activity
  • Breast Cancer
  • Colorectal Cancer

Dr. Slattery is a molecular epidemiologist whose major research focus on genetic and environmental interactions and tumor phenotypes associated with survival. In 1986 she moved to the University of Utah, where she has been involved in studies involving diverse population groups. Dr. Slattery has actively done research relating to epidemiological methods, exploring ways to analyze and interpret epidemiological data. Most of her research has been in the area of cancer, focusing primarily on colon and breast cancer, and she has been active in evaluating the role of genetic susceptibility to cancer development and survival. To gain a better understanding of specific cancer pathways, she has been evaluating how diet, activity and other lifestyle factors relate to the development of specific genetic alterations in tumors.

Slattery received a B.A. in microbiology at the University of Kansas, an M.P.H. with a focus on nutrition from the University of Minnesota, School of Public Health, and a Ph.D. in epidemiology with minors in biostatistics and nutrition from the University of Texas, School of Public Health in Houston. She is an active contributor to the scientific literature and performs peer review for 27 professional journals. Dr. Slattery is a member of the Society for Epidemiologic Research, American Association for Cancer Research, American Association of Human Genetics, and the American Association for Preventive Oncology.

Education History

Doctoral Training University of Texas
 PhD
Graduate Training University of Minnesota
 MPH
Undergraduate University of Kansas
 BA

Selected Publications

Journal Article

  1. Slattery ML, John EM, Torres-Mejia G, Lundgreen A, Lewinger JP, Stern MC, Hines L, Baumgartner KB, Giuliano AR, Wolff RK (2014). Angiogenesis genes, dietary oxidative balance and breast cancer risk and progression: the Breast Cancer Health Disparities Study. Int J Cancer, 134(3), 629-44.
  2. Boone SD, Baumgartner KB, Baumgartner RN, Connor AE, Pinkston CM, John EM, Hines LM, Stern MC, Giuliano AR, Torres-Mejia G, Brock GN, Groves FD, Kerber RA, Wolff RK, Slattery ML (2013). Associations between genetic variants in the TGF-beta signaling pathway and breast cancer risk among Hispanic and non-Hispanic white women. Breast Cancer Res Treat, 141(2), 287-97.
  3. Slattery ML, John EM, Stern MC, Herrick J, Lundgreen A, Giuliano AR, Hines L, Baumgartner KB, Torres-Mejia G, Wolff RK (2013). Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat, 140(3), 587-601.
  4. Fejerman L, Stern MC, Ziv E, John EM, Torres-Mejia G, Hines LM, Wolff R, Wang W, Baumgartner KB, Giuliano AR, Slattery ML (2013). Genetic ancestry modifies the association between genetic risk variants and breast cancer risk among Hispanic and non-Hispanic white women. Carcinogenesis, 34(8), 1787-93.
  5. Slattery ML, John EM, Torres-Mejia G, Herrick JS, Giuliano AR, Baumgartner KB, Hines LM, Wolff RK (2013). Genetic variation in bone morphogenetic proteins and breast cancer risk in hispanic and non-hispanic white women: The breast cancer health disparities study. Int J Cancer, 132(12), 2928-39.
  6. Bondurant KL, Lundgreen A, Herrick JS, Kadlubar S, Wolff RK, Slattery ML (2013). Interleukin genes and associations with colon and rectal cancer risk and overall survival. Int J Cancer, 132(4), 905-15.
  7. Pellatt AJ, Wolff RK, John EM, Torres-Mejia G, Hines LM, Baumgartner KB, Giuliano AR, Lundgreen A, Slattery ML (2013). SEPP1 influences breast cancer risk among women with greater native american ancestry: the breast cancer health disparities study. PLoS One, 8(11), e80554.
  8. Slattery ML, John E, Torres-Mejia G, Stern M, Lundgreen A, Hines L, Giuliano A, Baumgartner K, Herrick J, Wolff RK (2013). Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PLoS One, 8(5), e63165.
  9. Slattery ML, Lundgreen A, Wolff RK (2012). MAP kinase genes and colon and rectal cancer. Carcinogenesis, 33(12), 2398-408.
  10. Connor AE, Baumgartner RN, Baumgartner KB, Kerber RA, Pinkston C, John EM, Torres-Mejia G, Hines L, Giuliano A, Wolff RK, Slattery ML (2012). Associations between TCF7L2 polymorphisms and risk of breast cancer among Hispanic and non-Hispanic white women: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat, 136(2), 593-602.
  11. Slattery ML, John EM, Torres-Mejia G, Lundgreen A, Herrick JS, Baumgartner KB, Hines LM, Stern MC, Wolff RK (2012). Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population. Carcinogenesis, 33(8), 1512-21.
  12. Slattery ML, Herrick JS, Bondurant KL, Wolff RK (2012). Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Int J Cancer, 130(12), 2974-80.
  13. Slattery ML, Lundgreen A, Herrick JS, Kadlubar S, Caan BJ, Potter JD, Wolff RK (2012). Genetic variation in bone morphogenetic protein and colon and rectal cancer. Int J Cancer, 130(3), 653-64.
  14. Slattery ML, Lundgreen A, Welbourn B, Corcoran C, Wolff RK (2012). Genetic variation in selenoprotein genes, lifestyle, and risk of colon and rectal cancer. PLoS One, 7(5), e37312.
  15. Slattery ML, Lundgreen A, Bondurant KL, Wolff RK (2011). Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis, 32(11), 1660-7.
  16. Slattery ML, Baumgartner KB, Giuliano AR, Byers T, Herrick JS, Wolff RK (2011). Replication of five GWAS-identified loci and breast cancer risk among Hispanic and non-Hispanic white women living in the Southwestern United States. Breast Cancer Res Treat, 129(2), 531-9.
  17. Slattery ML, Curtin K, Poole EM, Duggan DJ, Samowitz WS, Peters U, Caan BJ, Potter JD, Ulrich CM (2011). Genetic variation in C-reactive protein in relation to colon and rectal cancer risk and survival. Int J Cancer, 128(11), 2726-34.
  18. Slattery ML, Herrick JS, Lundgreen A, Wolff RK (2011). Genetic variation in the TGF-beta signaling pathway and colon and rectal cancer risk. Cancer Epidemiol Biomarkers Prev, 20(1), 57-69.
  19. Rollison DE, Giuliano AR, Risendal BC, Sweeney C, Boulware D, Laronga C, Baumgartner KB, Byers T, Slattery ML (2010). Serum insulin-like growth factor (IGF)-1 and IGF binding protein-3 in relation to breast cancer among Hispanic and white, non-Hispanic women in the US Southwest. Breast Cancer Res Treat, 121(3), 661-9.
  20. Curtin K, Samowitz WS, Wolff RK, Ulrich CM, Caan BJ, Potter JD, Slattery ML (2009). Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer. Cancer Epidemiol Biomarkers Prev, 18(12), 3384-8.
  21. Slattery ML, Fitzpatrick FA (2009). Convergence of hormones, inflammation, and energy-related factors: a novel pathway of cancer etiology. Cancer Prev Res (Phila), 2(11), 922-30.
  22. Slattery ML, Wolff RK, Herrick J, Caan BJ, Samowitz W (2009). Tumor markers and rectal cancer: support for an inflammation-related pathway. Int J Cancer, 125(7), 1698-704.
  23. Curtin K, Samowitz WS, Wolff RK, Herrick J, Caan BJ, Slattery ML (2009). Somatic alterations, metabolizing genes and smoking in rectal cancer. Int J Cancer, 125(1), 158-64.
  24. Campbell PT, Curtin K, Ulrich CM, Samowitz WS, Bigler J, Velicer CM, Caan B, Potter JD, Slattery ML (2009). Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut, 58(5), 661-7.

Patent

  1. Samowitz W, Slattery ML, Wolff RK (2018). BRAF Mutations are Indicators of Poor Prognosis and Potential Therapy in Cancer U-3910.